Warning! GuruFocus detected
1 Severe warning sign
with CRDL.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Cardiol Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA14161Y2006
Share Class Description:
CRDL: Class ACompare
Compare
Traded in other countries / regions
CRDL.CanadaCRDL.USACT9.Germany IPO Date
2019-01-15Description
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 95.69 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 12.6 | |||||
| 3-Year EPS without NRI Growth Rate | 14.4 | |||||
| 3-Year FCF Growth Rate | -8.5 | |||||
| 3-Year Book Growth Rate | 2.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -16.95 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.73 | |||||
| 9-Day RSI | 29.19 | |||||
| 14-Day RSI | 34.61 | |||||
| 3-1 Month Momentum % | -12.21 | |||||
| 6-1 Month Momentum % | -44.44 | |||||
| 12-1 Month Momentum % | -36.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.49 | |||||
| Quick Ratio | 2.49 | |||||
| Cash Ratio | 2.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.8 | |||||
| Shareholder Yield % | -0.07 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -165.81 | |||||
| ROA % | -116.78 | |||||
| ROIC % | -2785.33 | |||||
| 3-Year ROIIC % | 4712.95 | |||||
| ROC (Joel Greenblatt) % | -12687.09 | |||||
| ROCE % | -174.62 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 9.26 | |||||
| Price-to-Tangible-Book | 9.6 | |||||
| EV-to-EBIT | -2.53 | |||||
| EV-to-Forward-EBIT | -5.15 | |||||
| EV-to-EBITDA | -2.55 | |||||
| EV-to-Forward-Revenue | 0.43 | |||||
| EV-to-FCF | -3.73 | |||||
| Price-to-Net-Current-Asset-Value | 9.6 | |||||
| Price-to-Net-Cash | 10.67 | |||||
| Earnings Yield (Greenblatt) % | -39.53 | |||||
| FCF Yield % | -23.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CRDL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cardiol Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.398 | ||
| Beta | 1.19 | ||
| 3-Year Sharpe Ratio | 0.12 | ||
| 3-Year Sortino Ratio | 0.22 | ||
| Volatility % | 55.09 | ||
| 14-Day RSI | 34.61 | ||
| 14-Day ATR ($) | 0.091412 | ||
| 20-Day SMA ($) | 1.10472 | ||
| 12-1 Month Momentum % | -36.46 | ||
| 52-Week Range ($) | 0.9149 - 3.12 | ||
| Shares Outstanding (Mil) | 81.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cardiol Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cardiol Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cardiol Therapeutics Inc Frequently Asked Questions
What is Cardiol Therapeutics Inc(CRDL)'s stock price today?
The current price of CRDL is $0.96. The 52 week high of CRDL is $3.12 and 52 week low is $0.91.
When is next earnings date of Cardiol Therapeutics Inc(CRDL)?
The next earnings date of Cardiol Therapeutics Inc(CRDL) is 2025-05-14 Est..
Does Cardiol Therapeutics Inc(CRDL) pay dividends? If so, how much?
Cardiol Therapeutics Inc(CRDL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers